Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Pandemic Is Hitting Hospitals Hard, Including Their Bottom LineGot a Vaccine-Skeptical Relative? Here's How to Talk to Them1 in 3 Americans Delayed, Skipped Medical Care During PandemicHealth Care After COVID: A New Focus on Infectious DiseasesMost Americans Unhappy With U.S. Vaccine Rollout: PollBedside Manner Even More Important for Hospital Patients Admitted Via the ERToo Many U.S. Doctors Biased Against Patients With Disabilities: StudyWhy Do Black Children Get Fewer Scans When They're Seen in ERs?Compared to Other Countries, Americans Pay Much More for Prescription DrugsAnti-Vaxxers Mounting Internet Campaigns Against COVID-19 ShotsPandemic Has Greatly Slowed Pace of Cancer ResearchCrowdsourcing Raises Billions for Families Hit Hard by Medical BillsBiden Says He Will Release All Vaccine Doses After Taking Office1 in 4 Doctors Harassed Online, Study FindsMoves, Evictions Often Trigger Harmful Breaks in Health Care: StudySome Americans Can't Access Telemedicine, Study ShowsHealth Care After COVID: The Rise of TelemedicineNeurologists Much Tougher to Find in Rural AmericaAs Testing Costs Rise, Neurology Patients May Skip Screening1 in 7 Studies in Nutrition Journals Have Food Industry TiesUSPS Cuts Could Pose Harm If Mail-Order Meds Delayed: Study329 Americans Are Injured by Guns Every Day: StudySome Talc Products Contain Asbestos: StudyAHA News: Why People Fear Performing CPR on Women – and What to Do About It'Green Prescriptions' May Backfire for SomePreventive Health Care Falls by Wayside During PandemicSmoking Bans Don't Work If Not Enforced, NYC Study FindsTelemedicine Out of Reach for Those Who Can't Get OnlineLies Spread on Social Media May Mean Fewer Vaccinations1 in 3 Americans Prescribed Inappropriate DrugsColon Cancer Screening Should Start at Age 45: Task ForceWhat Will It Take for People to Embrace a COVID Vaccine?What Will Convince Americans to Get a COVID-19 Vaccine?CDC Recommends Face Masks in All Public Transportation SettingsInsured Patients Are Getting Surprise Bills After ColonoscopiesBogus 'Cure' Claims Have U.S. Consumers Snapping Up CBD ProductsPediatricians' Group Tackles Racism in Health CareAs Virtual Doctor Visits Spike, Concerns About Equity, Missed Diagnoses GrowWas FDA Lax in Approving Opioids Too Easily?Allowing More Gay Men to Donate Corneas Could Save Sight for Thousands: StudyAccuracy of COVID-19 Antibody Tests Varies Widely, Study FindsCould Drones Delivering Defibrillators Save Lives?Statins Going Generic Saved Medicare BillionsAHA News: Looming Wave of Evictions, Housing Instability Pose Threat to HealthAHA News: Health Apps Pose Privacy Risks, But Experts Offer This AdviceCould You Save a Life After Mass Violence? Most Americans Say NoGun Violence Costs U.S. Health Care System $170 Billion AnnuallyWith COVID Vaccine in Works, 1 in 5 Americans Doesn't Believe in ShotsTelehealth Skyrocketing Among Older AdultsPharmacists in All U.S. States Can Give Kids Childhood Shots
Links
Related Topics

Health Insurance
Healthcare

COVID-19 Clinical Trials Lack Diversity, Researchers Say

HealthDay News
by -- Steven Reinberg
Updated: Aug 17th 2020

new article illustration

MONDAY, Aug. 17, 2020 (HealthDay News) -- Although minorities are paying a disproportionate price in the rate of COVID-19 illnesses and deaths, they are underrepresented in clinical trials, a new study finds.

The researchers call upon the government, medical journals and funders of research to make sure trials include minorities so that the results can be extrapolated to the U.S. population.

In the Adaptive COVID-19 Treatment Trial involving more than 1,000 patients testing the efficacy of the antiviral remdesivir, only 20% of participants are Black and 23% are Hispanic or Native American.

In the clinical trial funded by the drug's maker, Gilead, with nearly 400 patients, only 11% are Black and less than 1% are Hispanic or Native American.

"The overwhelming majority of the patients in both of those large clinical trials were Caucasians," said researcher Daniel Chastain, a clinical assistant professor of pharmacy at the University of Georgia's Albany campus.

"Knowing that African Americans die at a higher rate than Caucasians, can I say that this medication will work in them as well? Yes, they enrolled a bunch of patients and yes they got these data out as fast as possible, but can we use this information to inform treatments in all patients?" he said in a university news release.

The remdesivir trials found that patients given the drug recovered from COVID-19 a little faster than those given a placebo. But minority patients often have more severe symptoms and complications from the disease, so it's not clear if they will respond as well to the drug.

"Why aren't we putting up infrastructure for clinical trial sites in areas that were heavily hit by COVID?" Chastain said. "If we would've included Albany, those clinical trials would've been more diversified and would've been much more representative of what the coronavirus pandemic looks like in our area and throughout the U.S."

The report was published Aug. 12 in the New England Journal of Medicine.

More information

For more on COVID-19, head to the U.S. Centers for Disease Control and Prevention.




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net